NEW AMBRX BIOPHARMA INC (AMAM)
US6418711080 - Common Stock
Taking everything into account, AMAM scores 4 out of 10 in our fundamental rating. AMAM was compared to 587 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for AMAM as it has an excellent financial health rating, but there are worries on the profitability. AMAM is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year AMAM has reported negative net income.
1.2 Ratios
The Return On Assets of AMAM (-30.43%) is better than 72.73% of its industry peers.
AMAM's Return On Equity of -34.09% is fine compared to the rest of the industry. AMAM outperforms 78.28% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -30.43% | ||
| ROE | -34.09% | ||
| ROIC | N/A |
ROA(3y)-31.71%
ROA(5y)N/A
ROE(3y)-38.85%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for AMAM so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
AMAM does not have a ROIC to compare to the WACC, probably because it is not profitable.
AMAM has about the same amout of shares outstanding than it did 1 year ago.
There is no outstanding debt for AMAM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
AMAM has an Altman-Z score of 254.13. This indicates that AMAM is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 254.13, AMAM belongs to the best of the industry, outperforming 99.66% of the companies in the same industry.
AMAM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 254.13 |
ROIC/WACCN/A
WACC8.93%
2.3 Liquidity
A Current Ratio of 12.78 indicates that AMAM has no problem at all paying its short term obligations.
AMAM's Current ratio of 12.78 is amongst the best of the industry. AMAM outperforms 84.51% of its industry peers.
AMAM has a Quick Ratio of 12.78. This indicates that AMAM is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 12.78, AMAM belongs to the best of the industry, outperforming 84.51% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 12.78 | ||
| Quick Ratio | 12.78 |
3. Growth
3.1 Past
AMAM shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -16.00%.
Looking at the last year, AMAM shows a decrease in Revenue. The Revenue has decreased by -0.80% in the last year.
Measured over the past years, AMAM shows a very negative growth in Revenue. The Revenue has been decreasing by -10.47% on average per year.
EPS 1Y (TTM)-16%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2QN/A
Revenue 1Y (TTM)-0.8%
Revenue growth 3Y-10.47%
Revenue growth 5YN/A
Revenue growth Q2QN/A
3.2 Future
The Earnings Per Share is expected to decrease by -25.23% on average over the next years. This is quite bad
AMAM is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 38.47% yearly.
EPS Next Y-159.66%
EPS Next 2Y-135.39%
EPS Next 3Y-38.21%
EPS Next 5Y-25.23%
Revenue Next Year-57.14%
Revenue Next 2Y-45.32%
Revenue Next 3Y-4.12%
Revenue Next 5Y38.47%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for AMAM. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AMAM. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
AMAM's earnings are expected to decrease with -38.21% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-135.39%
EPS Next 3Y-38.21%
5. Dividend
5.1 Amount
No dividends for AMAM!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NEW AMBRX BIOPHARMA INC
NASDAQ:AMAM (3/6/2024, 7:00:01 PM)
After market: 28 0 (0%)28
+0.02 (+0.07%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap12.42B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -30.43% | ||
| ROE | -34.09% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.02
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 12.78 | ||
| Quick Ratio | 12.78 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-16%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-159.66%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-0.8%
Revenue growth 3Y-10.47%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y